Schlieren, Switzerland
InterAx Biotech, founded in 2016, is a pioneering spin-out from ETH Zurich and the Paul Scherrer Institute in Switzerland. The company is at the forefront of integrating biological systems with advanced mathematical models and artificial intelligence, as highlighted in their slogan: "Advanced integration of biological systems, math models and artificial intelligence."
By employing high throughput biochemical screening and AI-driven cell pathway modeling, InterAx Biotech aims to revolutionize drug discovery. Their platform efficiently unlocks previously challenging targets, drastically reducing timelines from years to mere months while minimizing risks. The company's expertise in GPCR drug discovery covers a comprehensive range from hit-generation to lead optimization, including orphan GPCRs.
With its last known Fr.3.00M Series A investment on 01 January 2019 from prominent investors Verve Ventures and Falkon Ventures, InterAx Biotech is poised to advance its research and development capabilities in the AI, biopharma, and biotechnology industries.
